These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 20876067)

  • 1. Anticoagulation in percutaneous coronary interventions: no man's land?
    Nef HM; Möllmann H; Hamm CW
    Eur Heart J; 2010 Oct; 31(20):2447-8. PubMed ID: 20876067
    [No Abstract]   [Full Text] [Related]  

  • 2. Unfractionated versus low-molecular-weight heparin for primary angioplasty-More data suggesting to go low.
    Moliterno DJ
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):191-2. PubMed ID: 21290553
    [No Abstract]   [Full Text] [Related]  

  • 3. Drugs for percutaneous coronary interventions.
    Med Lett Drugs Ther; 2004 Dec 6-20; 47(1197-1198):100-2. PubMed ID: 15583527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Standard pharmacological therapy associated with percutaneous coronary interventions in patients with stable angina].
    Karcz M; Ruzyłło W
    Kardiol Pol; 2004 Nov; 61(11):480-2. PubMed ID: 15883598
    [No Abstract]   [Full Text] [Related]  

  • 5. Platelets and coronary artery disease.
    Handin RI
    N Engl J Med; 1996 Apr; 334(17):1126-7. PubMed ID: 8598874
    [No Abstract]   [Full Text] [Related]  

  • 6. [Current approach in antithrombotic treatment during coronary interventions: specific thrombocyte aggregation inhibitors and direct thrombin antagonists in high-risk patients].
    Meyer BJ
    Schweiz Med Wochenschr; 1996 Nov; 126(46):1961-9. PubMed ID: 8984604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extensive thrombus prior to elective percutaneous coronary intervention.
    Kandzari DE; Behar VS; Sketch MH; Kereiakes DJ; Shimshak T; Broderick T; Young J; Runyon JP; Safian RD; Kern M; Colombo A
    J Invasive Cardiol; 2001 Jul; 13(7):538-42. PubMed ID: 11435643
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel.
    Sibbing D; von Beckerath N; Morath T; Stegherr J; Mehilli J; Sarafoff N; Braun S; Schulz S; Schömig A; Kastrati A
    Eur Heart J; 2010 May; 31(10):1205-11. PubMed ID: 20159881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in post stenting medication protocol.
    Morice MC
    J Invasive Cardiol; 1995; 7 Suppl A():32A-35A. PubMed ID: 10155114
    [No Abstract]   [Full Text] [Related]  

  • 10. Enoxaparin for anticoagulation in patients undergoing percutaneous coronary intervention.
    James S
    BMJ; 2012 Feb; 344():e712. PubMed ID: 22306481
    [No Abstract]   [Full Text] [Related]  

  • 11. Optimized combination of antiplatelet treatment and anticoagulation for percutaneous coronary intervention: the final word is not out yet!
    Gruberg L; Beyar R
    J Invasive Cardiol; 2002 May; 14(5):251-3. PubMed ID: 11983946
    [No Abstract]   [Full Text] [Related]  

  • 12. [Complication of percutaneous coronary intervention--coronary dissection and acute closure].
    Mitsudo K
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():518-23. PubMed ID: 12735026
    [No Abstract]   [Full Text] [Related]  

  • 13. [Longterm treatment of POAD with anticoagulants and platelet inhibitors after endovascular procedures and vascular surgery: what is evidence based?].
    Landgraf H
    Hamostaseologie; 2006 Aug; 26(3):239-44; quiz 245-6. PubMed ID: 16906242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regarding antithrombotic treatment after coronary stenting in patients on chronic oral anticoagulation.
    Rubboli A; Colletta M; Di Pasquale G
    Am Heart J; 2005 Feb; 149(2):E1. PubMed ID: 15846242
    [No Abstract]   [Full Text] [Related]  

  • 15. New anticoagulant strategies.
    Weitz J; Hirsh J
    J Lab Clin Med; 1993 Oct; 122(4):364-73. PubMed ID: 8228551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do not adjust the platelet count in light transmittance aggregometry when predicting thrombotic events after percutaneous coronary intervention.
    Breet NJ; VAN Werkum JW; Bouman HJ; Kelder JC; Ten Berg JM; Hackeng CM
    J Thromb Haemost; 2010 Oct; 8(10):2326-8. PubMed ID: 20695984
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of prostacyclin on platelets, polymorphonuclear cells, and heterotypic cell aggregation during hemofiltration.
    Kozek-Langenecker SA; Spiss CK; Michalek-Sauberer A; Felfernig M; Zimpfer M
    Crit Care Med; 2003 Mar; 31(3):864-8. PubMed ID: 12626998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet treatment for coronary heart disease.
    Clappers N; Brouwer MA; Verheugt FW
    Heart; 2007 Feb; 93(2):258-65. PubMed ID: 17228079
    [No Abstract]   [Full Text] [Related]  

  • 19. The good, the bad, and the ugly: triple therapy after PCI in patients requiring chronic anticoagulation.
    Sinnaeve PR
    Eur Heart J; 2007 Mar; 28(6):657-8. PubMed ID: 17332009
    [No Abstract]   [Full Text] [Related]  

  • 20. [Anticoagulation in transitory ischemic attack after bypass surgery].
    Bruhn HD
    Dtsch Med Wochenschr; 1997 Feb; 122(7):210. PubMed ID: 9072493
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.